Accession Number : ADA435100


Title :   Treatment Strategies fir the NMDA Component of Organophosphorous Convulsions


Descriptive Note : Final rept. 1 Sep 2003-31 Mar 2005


Corporate Author : NEW MEXICO UNIV ALBUQUERQUE HEALTH SCIENCES CENTER


Personal Author(s) : Peterson, Steven


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a435100.pdf


Report Date : Apr 2005


Pagination or Media Count : 83


Abstract : The project evaluated anticonvulsant and neuroprotectant properties of novel medical countermeasures to lithium-pilocarpine-induced status epilepticus (SE)used here as a model of organophosphorus nerve agents. Although mefenamate induced modest anticonvulsant effects, survival was reduced and the SE-induced neuropathology was exacerbated. Nicotinamide induced only modest anticonvulsant and neuroprotectant activity at the doses tested. N-acetylcysteine was not anticonvulsant but enhanced both neurological deficit and neuropathology. PBN, but not S-PBN, induced significant neuroprotection. ACPC induced neuroprotection in temporal regions without anticonvulsant activity. D-cycloserine had no effect. Propofol induced significant neuroprotection and anticonvulsant activity in the rat model tested. It is recommended that PEN and ACPC be tested in multiple dose regimens for long term neuroprotection in nerve agent SE.


Descriptors :   *NERVE AGENTS , *ORGANOPHOSPHATES , *ANTICONVULSANTS , SURVIVAL(GENERAL) , DEFICIENCIES , CHEMICAL AGENTS , DOSAGE , NERVE CELLS , COUNTERMEASURES , NEUROTOXINS , VITAMIN B COMPLEX , CONVULSIVE DISORDERS


Subject Categories : Anatomy and Physiology
      Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE